Is Cdc25 a druggable target?
Proper control of cell cycle progression requires the functionality of a small family of activating phosphatases termed Cdc25, which have been implicated in cancer and Alzheimer's disease. These protein tyrosine phosphatases are therefore recognized as attractive molecular targets for small molecules. We review the rationale, approaches, progress and challenges for developing small molecule inhibitors of the Cdc25 family. A number of potential chemical probes are discussed and their characteristics are summarized.
Lazo
John S
JS
Department of Pharmacology and Chemical Biology, Drug Discovery Institute, University of Pittsburgh, Pittsburgh, PA 15260, USA. lazo@pitt.edu
Wipf
Peter
P
D000818:Animals; D002453:Cell Cycle; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006801:Humans; D020687:cdc25 Phosphatases / Q000037:antagonists & inhibitors*
D004791:Enzyme Inhibitors; D020687:cdc25 Phosphatases